Membership of the Royal College of Physicians of Ireland

Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Association of American Physicians, Faculty, American College, ASCO, Dean, MD Anderson Cancer Center, Vice, Clinical professor, Hematology, American Society of Clinical Oncology, Advisory board, University of Nebraska Medical Center, Department of Medicine – University of Pamplona, Clinical Oncology, Society, Internal medicine, UNMC, College, Membership of the Royal College of Physicians of Ireland, Royal college, Nebraska Medicine, Division, Richard, University, American College of Physicians, Mayo Clinic, Cancer, Patient, American Association for Cancer Research, Transplant, Book, Coronavirus Scientific Advisory Board, Pharmaceutical industry, Nursing, Medical device, Physician

Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.

Key Points: 
  • Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.
  • Dr. Armitage has served as President of both the American Society for Transplantation and Cellular Therapy (ASTCT) and the American Society of Clinical Oncology (ASCO).
  • “We are deeply honored to have Dr. Armitage join Syncromune’s Scientific Advisory Board as chair,” stated Eamonn Hobbs, President and CEO of Syncromune.
  • He has authored or co-authored more than 600 articles and 100 book chapters and is the editor/co-editor of 27 books.

InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Mark Levick, MD, Ph.D. as New Board Director

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Faculty, GSK, Royal college, University, Drug development, Senior, Tropical medicine, G protein-coupled receptor, Levick, University of Cambridge, Membership of the Royal College of Physicians of Ireland, Cancer, ETH Zurich, Faculty of Pharmaceutical Medicine, Multimedia, Biomarker, Computational chemistry, Doctor of Philosophy, Language, Paul Scherrer Institute, GPCR, Novartis, MD, Vivo, Drug discovery, Commonwealth Scholarship and Fellowship Plan, Artificial intelligence, Marie Cassidy, FRCPA, University of Newcastle, Pharmaceutical medicine, Pharmacology, Medical device, Pharmaceutical industry, EU, Physician, AI

InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.

Key Points: 
  • InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20231003682932/en/
    Dr. Mark Levick, MD, Newly appointed Board Director of InterAx Biotech (Photo: Business Wire)
    Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ.
  • In addition to building the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries.
  • Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development.

enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

Retrieved on: 
Thursday, September 7, 2023
Puma Biotechnology, Bachelor, Royal college, Biotechnology, University, Therapy, RCOG, Engen Botswana Limited, Bachelor of Medicine, Bachelor of Surgery, Membership of the Royal College of Physicians of Ireland, MRCGP, RCP, Carfilzomib, DDX, Royal Navy, Onyx Pharmaceuticals, EMA, LEGEND, Science, Patient, Liposarcoma, Chief medical informatics officer, Commander of the Navy (Sri Lanka), Growth, FDA, Puma, Pharmaceutical industry, EU, NMIBC, Medicine

"We are thrilled to have Dr. Bryce join enGene during a pivotal period in our growth as we advance our Phase 1/2 registrational LEGEND study for EG-70 in NMIBC," said Jason Hanson, CEO of enGene.

Key Points: 
  • "We are thrilled to have Dr. Bryce join enGene during a pivotal period in our growth as we advance our Phase 1/2 registrational LEGEND study for EG-70 in NMIBC," said Jason Hanson, CEO of enGene.
  • Before joining enGene, Dr. Bryce was most recently Chief Medical Officer at Rain Oncology, a late-stage company developing precision oncology therapeutics, where he built a clinical development team and oversaw multiple clinical studies, including a global Phase 3 registrational study in dedifferentiated liposarcoma.
  • Prior to that, he was Chief Medical & Scientific Officer at Puma Biotechnology, where he led the development strategy for neratinib.
  • He also served as a Surgeon Lieutenant Commander in the Royal Navy.

Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 13, 2023
Bevacizumab, Food allergy, Omalizumab, Development, Journal, Division, Risk, Clinical scientist, Faculty, CD117, University, Option, Coronavirus Scientific Advisory Board, Genentech, Alagille syndrome, UCSF, Biology, Immunology, FDA, Medical school, Royal college, Employment, CSU, University of California, Davis, Hives, Assistant, B cell, Syndrome, Therapy, Janssen Pharmaceuticals, Drug development, Tuba Mirum (Paus), Ascending cholangitis, Berkeley, Membership of the Royal College of Physicians of Ireland, Pharmacyclics, AstraZeneca, School, Bayer, Pharmaceutical industry, Jasper, Pharmacology, Medicine

REDWOOD CITY, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Edwin J. Tucker as Jasper’s Chief Medical Officer. Concurrently, Jasper also announced the appointment of Dr. Daniel Adelman, who had been serving as Jasper’s Acting Chief Medical Officer, to its Scientific Advisory Board and to the position of Senior Clinical Advisor.

Key Points: 
  • Concurrently, Jasper also announced the appointment of Dr. Daniel Adelman, who had been serving as Jasper’s Acting Chief Medical Officer, to its Scientific Advisory Board and to the position of Senior Clinical Advisor.
  • He was most recently Chief Medical Officer at Goldfinch Bio, where he led clinical development and helped build the regulatory, medical affairs and clinical operations functions.
  • Dr. Adelman has held several leadership roles within the biopharma industry throughout his career, including Chief Medical Officer at Aimmune Therapeutics, Alvine Pharmaceuticals and Sunesis Pharmaceuticals.
  • In connection with the appointment of Dr. Tucker as its Chief Medical Officer, on June 12, 2023, Jasper granted Dr. Tucker an option to purchase 400,000 shares of voting common stock (the “Option”).